Cargando…
Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56
The inhibitory receptors PD-1, Tim-3, and Lag-3 are highly expressed on tumor-infiltrating lymphocytes and compromise their antitumor activity. For efficient cancer immunotherapy, it is important to prevent chimeric antigen receptor T (CAR-T)-cell exhaustion. Here we downregulate these three checkpo...
Autores principales: | Zou, Fan, Lu, Lijuan, Liu, Jun, Xia, Baijin, Zhang, Wanying, Hu, Qifei, Liu, Weiwei, Zhang, Yiwen, Lin, Yingtong, Jing, Shuliang, Huang, Mei, Huang, Bifen, Liu, Bingfeng, Zhang, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739330/ https://www.ncbi.nlm.nih.gov/pubmed/31511513 http://dx.doi.org/10.1038/s41467-019-11893-4 |
Ejemplares similares
-
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins
por: Qiao, Yidan, et al.
Publicado: (2023) -
Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef–AP-1 Complex Formation: A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells
por: Liu, Bingfeng, et al.
Publicado: (2019) -
Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023) -
Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection
por: Zhang, Wanying, et al.
Publicado: (2022) -
The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity
por: Zou, Fan, et al.
Publicado: (2021)